title: Effects of combined bezafibrate-simvastatin appraised in healthy subjects.
abstract: The occurrence of clinical and biochemical side effects of bezafibrate (400 mg daily) or simvastatin (20 mg daily) alone or combined was appraised in 13 healthy male normolipidemic subjects according to a single blind design. Each period of 2 weeks of treatment with bezafibrate or simvastatin or bezafibrate plus simvastatin was followed by a period of placebo (1 week). No subjects experienced myalgia or muscle weakness. Plasma creatine kinase (CK) elevations, particularly skeletal muscle CK (CK-MM), were observed in 6 subjects: 11 times during different placebo periods, 5 times on bezafibrate, 4 times on simvastatin, and 4 times on combined bezafibrate-simvastatin, but never reached 1,600 IU/L. Only a trend to an increase of CK mean values on combined bezafibrate-simvastatin was shown. The hepatic transaminase and gamma-glutamyltransferase activities remained unmodified throughout the trial, unlike alkaline phosphatase activity, which fell on bezafibrate and on bezafibrate plus simvastatin. The low-density lipoprotein cholesterol level was more reduced with simvastatin than with bezafibrate. The addition of bezafibrate to simvastatin did not decrease it further. Lecithin:cholesterol acyltransferase activity expressed as fractional esterification rate was enhanced only on simvastatin and bezafibrate-simvastatin.
authors.affiliation: Laboratoire de Pharmacothérapie, Université Catholique de Louvain, Brussels, Belgium.
authors.forename: Y
authors.initials: Y
authors.lastname: Horsmans
authors.forename: J P
authors.initials: JP
authors.lastname: Desager
authors.forename: C
authors.initials: C
authors.lastname: Harvengt
mesh_terms: D000328:Adult; D000924:Anticholesteremic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D001629:Bezafibrate / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006801:Humans; D008055:Lipids / Q000097:blood; D008148:Lovastatin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology; D008297:Male; D009132:Muscles; D010146:Pain / Q000139:chemically induced; D007862:Phosphatidylcholine-Sterol O-Acyltransferase / Q000097:blood; D019821:Simvastatin
chemical_list: D000924:Anticholesteremic Agents; D008055:Lipids; D008148:Lovastatin; D019821:Simvastatin; D007862:Phosphatidylcholine-Sterol O-Acyltransferase; D001629:Bezafibrate